Navigation Links
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Date:12/4/2007

lasmin."

About Vitreomacular Traction

Numerous conditions are associated with vitreomacular traction which may lead to decreased vision and/or complications. These include macular hole, macular edema (ME) associated with vitreomacular traction, and vitreomacular traction syndrome (VTMS). The only available treatment for these conditions is surgical vitrectomy, in order to induce a posterior vitreous detachment (PVD) and thereby alleviate the vitreomacular traction. Therefore, a pharmacological agent that could relieve vitreomacular traction nonsurgically would be a dramatic advance for the treatment of these conditions, preventing the need for surgery and its associated cost, inconvenience and risk of complications. Macular hole prevalence is approximately 0.14% of general population, leading to estimates of approximately 400,000 cases in the US and of up to 1 million in the industrialized world.

Other potential nonsurgical applications for microplasmin include treatment of macular edema and diabetic retinopathy. Diabetic retinopathy is the leading cause of blindness among working-age adults while diabetic macular edema (DME) is the leading cause of decreased vision in patients with diabetic retinopathy. Around 750,000 patients suffer from DME in the United States alone.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular and eye diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which is expected to
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Not long ago, it was more or less ... in the development cycle – even after the final ... that, like many things GxP, expectations for early E&L ... drug sponsors have been required by authorities to provide ... I/II. It’s not only clinical trial material containers causing ...
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... A Geisinger researcher on a personal crusade ... for Disease Control and Prevention (CDC) award recognizing his ... Joseph Boscarino , Ph.D. MPH, senior ... of researchers nominated for the Centers for Disease Control ... Data Methods and Study Design. "Hepatitis C ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... aTyr Pharma, the physiocrine therapeutics company, today announced ... by Domain Associates.  Domain joins existing venture investors ... also participated in the financing.  Proceeds will be ... pipeline and advance physiocrine drug candidates into clinical ...
... announced that it has successfully modified yeast to be ... encountered in the bioproduction of fuel ethanol. In doing ... more ethanol. "We are very pleased ... developing a 2nd generation with yet better commercial performance ...
... ITHACA, N.Y. The human hand is an amazing ... but for a robot, this "gripping" mechanism is a vexing ... of Chicago and iRobot have bypassed traditional designs based around ... using everyday ground coffee and a latex party balloon. ...
Cached Biology Technology:aTyr Pharma Secures $23M Financing From Top Tier Venture Investor 2iDiverse Develops Stress Resistant Yeast for Producing Fuel Ethanol 2Robotic gripper runs on coffee ... and balloons 2
(Date:8/20/2014)... 20, 2014 George E. Fox, a John and Rebecca ... Houston (UH), was named a fellow in the International Society ... , Fox is one of four members two from ... chosen as fellows in 2014. Fellows are elected every three ... than 500 members from more than 20 countries, the ISSOL ...
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
(Date:8/20/2014)... /CNW/ -  Issue Serious allergic reactions ... life threatening for some children.    What you ... have food allergies and this number may be increasing, especially ... estimated to have food allergies.  The symptoms ... hives to breathing difficulties and loss of consciousness. Symptoms can ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Blueprint for next generation of chronic myeloid leukemia treatment 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... underfunding health: so what kind of new development paradigm will ... and where will sexual and reproductive health and rights (SRHR) ... latest themed issue of Reproductive Health Matters explore ... at the global policy level, and the evolution of the ...
... 9, 2013) A new study shows that high school ... closer to sea-level, a phenomenon attributed to physiological changes in ... skull. "This is the first time any research has ... professor of epidemiology at the Colorado School of Public Health ...
... , Dec. 9, 2013 Today, the country,s ... a Series D extension of $15 million in new ... its venture capital arm, Qualcomm Ventures, brings Practice Fusion,s ... raised to date at $149 million. The round was ...
Cached Biology News:Reproductive Health Matters announces publication of its latest themed issue: New development paradigm 2Study shows first link between altitude and concussion 2Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 2Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 3
... is a powerful application for DNA ... novel interface, Expression makes complex computational ... Expression uses the very latest computing ... the way sequences are analysed. Features ...
Topoisomerase II...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... General description: Dish uses include large-scale colony-counting ... with PBA Flexys TM automated colony ... is a new product number, created to ... no availability yet, please order under the ...
Biology Products: